The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer

SIMPLE SUMMARY: Nowadays, the upfront treatment for patients facing a diagnosis of advanced luminal breast cancer (BC) is a combination of endocrine therapy (ET) with an inhibitor of CDK4/6 (CDK4/6i), which effectively targets and prevents cell cycle progression in hormone-dependent BC. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Inês, Abreu, Catarina, Costa, Luis, Casimiro, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571967/
https://www.ncbi.nlm.nih.gov/pubmed/37835528
http://dx.doi.org/10.3390/cancers15194835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571967/
https://www.ncbi.nlm.nih.gov/pubmed/37835528
http://dx.doi.org/10.3390/cancers15194835

Ejemplares similares